StratDeck

Two stocks in Healthcare

NEUCA vs Novo Nordisk A/S: profit, growth, debt and price compared

Novo Nordisk A/S is stronger on 4 of 7 figures: profit margin, sales growth, price for its expected profit and dividend. NEUCA is stronger on 3: debt, analysts' view and price trend.

Figures as of 20 November 2026Yahoo Finance
Explore NEUCA's storyWhere next ↓

Save both stocks to your watchlist and revisit their latest fundamentals.

NEUCA and Novo Nordisk A/S side by side
NEUCANEU.WANovo Nordisk A/SNOVO-B.CO
Net margin1.4%Stronger: 33.9%
Revenue growth, past year+5.50%Stronger: +5.60%
Debt to equityStronger: 45.2%61.7%
Forward P/E13.2×Stronger: 11.7×
Dividend yield2.49%Stronger: 4.41%
AnalystsStronger: Strong buy · 5Hold · 24
From its 200-day averageStronger: −0.2%−9.3%

Share price over the past year

  • NEUCA−7.9%
  • Novo Nordisk A/S−14.9%

19 Nov 202520 Nov 2026

NEUCA or Novo Nordisk A/S: which is stronger?

  • NOVO-B.CO

    Which is more profitable?

    Novo Nordisk A/S keeps more of each sale as profit: 33.9% against 1.4%.

  • NOVO-B.CO

    Which is growing its sales faster?

    Novo Nordisk A/S is growing its sales faster: +5.60% over the past year, against +5.50%.

  • NEU.WA

    Which has borrowed less?

    NEUCA has borrowed less: its debt is 45.2% of what its shareholders own, against 61.7% for Novo Nordisk A/S.

  • NOVO-B.CO

    Which costs less for the profit it is expected to make?

    Novo Nordisk A/S costs less for the profit it is expected to make: 11.7× its forward earnings, against 13.2×.

  • NOVO-B.CO

    Which pays more in dividends?

    Novo Nordisk A/S pays more back in dividends for what a share costs: 4.41% a year, against 2.49%.

  • NEU.WA

    Which do analysts rate higher?

    Analysts are warmer on NEUCA: Strong buy, against Hold for Novo Nordisk A/S.

  • NEU.WA

    Which is in the stronger price trend?

    NEUCA's price is in the stronger trend: 0.2% below its 200-day average, against 9.3% below.

What each company does

NEU.WANEUCA

NEUCA S.A. engages in the wholesale distribution of pharmaceuticals in Poland.

NOVO-B.CONovo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products.

Reports results on 3 February 2027

This comparison is just the starting point.

Discover opportunities, understand companies and compare investments in one place. See how StratDeck works

Keep researching

Where next

Every European healthcare comparison

Free email

Up to speed in minutes, four times a week

Every Monday, know what moved AI stocks and what to watch next. Every Wednesday and Friday, find a stock worth a look and learn its story. Every Sunday, catch up on the market's week in two minutes.

Early access

Become a StratDeck founding user

Use StratDeck, tell us what's missing, and help decide what we build next.

100 founding places. Founding users get their first month free, then half price for life: £2.99 a month or £30 a year.